Johnson & Johnson says Ottava surgical robot met endpoints in pivotal bariatric surgery study

Johnson & Johnson announced that its Ottava surgical robot met primary safety and performance endpoints in its first clinical study, the FORTE study, involving Roux-en-Y gastric bypass procedures. This milestone follows the company’s submission of Ottava to the FDA for de novo approval in January. The Ottava system, which integrates four robotic arms into a standard surgical table and aims to address space constraints in operating rooms, is targeted for multiple general surgery procedures.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned